
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher has demonstrated strong growth potential, as evidenced by its increase in performance obligations from $4.5 billion in 1Q25 to $4.9 billion in 2Q25, indicating robust demand for its scientific instruments and consumables. The company is anticipating a ramp-up in the Life Sciences segment, projected at approximately 4.5% in 4Q25, driven by favorable comparisons in Genomics, recovery in China, and new product launches. Additionally, with the Cepheid Respiratory segment appearing de-risked and expected revenues of $300-350 million in 3Q25 and $450-500 million in 4Q25, the outlook for Danaher’s operational performance remains optimistic amidst strategic adjustments.
Bears say
Danaher's outlook presents concerns primarily due to a decline in expected revenue recognition from 2Q25 obligations, which fell from 48% to 46%. Additionally, the company faces significant risks from potential geopolitical disruptions, unfavorable foreign exchange conditions, and uncertainties regarding the recovery of high-growth markets, particularly in China. Despite slightly below-expected guidance for Biotechnology and Life Sciences revenue in 3Q25, these fundamental challenges cast doubt on the company's overall financial resilience.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares